Gal-1 is a β-galactoside binding protein that plays an important role in cancer progression and has been implicated in resistance to chemotherapy and anti-VEGF therapy. Gal-1 mediates glioma aggressiveness and its expression increases with grade and correlates with worse outcome. Our aim was to evaluate the prognostic significance of Gal-1 in a homogenous cohort of GB.
GLIOCAT is a multicenter study of newly diagnosed 432 GB patients treated with Stupp regimen. Tissue from 272 patients was used to generate a tissue microarray and Gal-1 expression in cytoplasm (C) and nucleus (N) was analyzed by immunohistochemistry. Results were evaluated by three reviewers and quantified by H-Score. Expression levels were correlated with clinical characteristics, known prognostic factors and response to anti-angiogenic treatment. Preliminary results will be presented at 2017 ASCO, abstract e13526. We will report here the final results.
We defined a cut off for Gal-1 H-Score of ≥ 157 (cytoplasm, C) and ≥123 (nucleus, N). High combined Gal-1 expression significantly correlated with worse OS. No correlation was found with PFS.Table:
|H-Score||n||mOS (months) (range)||p value|
|Combined H-Score Low (C |
Gal-1 expression represents an independent prognostic factor for GB patients treated initially with standard therapy and with other therapies at recurrence.
Clinical trial identification
Legal entity responsible for the study
Marató TV3 2012
All authors have declared no conflicts of interest.